Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19003301 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA | December 2024 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18945784 | Antibodies Targeting ActRIIA and ActRIIB | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18920412 | ANTI-PHOSPHOCHOLINE ANTIBODIES AND METHODS OF USE THEREOF | October 2024 | March 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18677564 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | May 2024 | May 2025 | Allow | 12 | 1 | 2 | No | No |
| 18585676 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | February 2024 | April 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18457687 | IMMUNOSILENCING Fc VARIANTS | February 2024 | June 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18523196 | ANTIBODIES DIRECTED TO CLAUDIN 6, INCLUDING BISPECIFIC FORMATS THEREOF | November 2023 | May 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18459892 | THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18458043 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY | August 2023 | June 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18330345 | TOLEROGENIC SYNTHETIC NANOCARRIERS | June 2023 | April 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18140289 | POLYMER-BASED MACROMOLECULAR PRODRUGS | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18189387 | ALK5 INHIBITORS AND THEIR USES | March 2023 | July 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18185999 | Methods of Treating Cancer Using Compositions of Antibodies and Carrier Proteins with Antibody Pretreatment | March 2023 | February 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18175786 | NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT | February 2023 | June 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18169767 | METHODS AND MATERIALS FOR ASSESSING RESPONSE TO PLASMABLAST- AND PLASMA CELL-DEPLETING THERAPIES | February 2023 | April 2025 | Allow | 26 | 1 | 1 | No | No |
| 18108514 | COMPOSITIONS OF PROTEIN COMPLEXES AND METHODS OF USE THEREOF | February 2023 | January 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18165233 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | February 2023 | July 2025 | Allow | 29 | 2 | 1 | No | No |
| 18006313 | IL28A RECEPTOR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE | January 2023 | July 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18156305 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | January 2023 | April 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18153228 | MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES | January 2023 | February 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18146044 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES | December 2022 | January 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18069151 | CHIMERIC POLYPEPTIDES AND USES THEREOF | December 2022 | April 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18067908 | CHIMERIC RECEPTOR BINDING PROTEINS RESISTANT TO PROTEOLYTIC DEGRADATION | December 2022 | November 2023 | Abandon | 11 | 2 | 1 | No | No |
| 18064211 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY | December 2022 | March 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17975362 | BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF | October 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17975333 | BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF | October 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17945729 | MARROW INFILTRATING LYMPHOCYTES (MILS) AS A SOURCE OF T-CELLS FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THEREAPY | September 2022 | June 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17939109 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | September 2022 | September 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17823905 | ANTI-CD38 ANTIBODIES | August 2022 | September 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17821688 | ANTIBODY MOLECULES WHICH BIND CD22 | August 2022 | December 2024 | Allow | 28 | 1 | 1 | No | No |
| 17892089 | ANTIGEN RECEPTORS AND USES THEREOF | August 2022 | March 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17888336 | Antibody Conjugates and Methods of Making and Using the Same | August 2022 | January 2025 | Allow | 29 | 1 | 1 | No | No |
| 17814488 | HUMAN ANTIBODIES BINDING TO ROR2 | July 2022 | December 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17870749 | USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR | July 2022 | January 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17861175 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17810480 | Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein | July 2022 | December 2024 | Allow | 30 | 1 | 1 | No | No |
| 17809846 | ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF | June 2022 | July 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17842573 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | June 2022 | February 2023 | Allow | 8 | 1 | 1 | No | No |
| 17806339 | MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION | June 2022 | January 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17664731 | ENGINEERED T CELLS AND USES THEREFOR | May 2022 | August 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17664609 | BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE | May 2022 | April 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17663393 | ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN AND THEIR METHODS OF USE | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17742707 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | May 2022 | September 2023 | Allow | 16 | 2 | 0 | No | No |
| 17660603 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS | April 2022 | August 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17726950 | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES | April 2022 | October 2024 | Allow | 30 | 5 | 1 | Yes | No |
| 17720523 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | April 2022 | June 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17716667 | ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF | April 2022 | May 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17694570 | BIFUNCTIONAL MOLECULES FOR TREATMENT OF IMMUNE DISORDERS | March 2022 | January 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17689290 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER | March 2022 | July 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17672573 | METHODS FOR TREATING B-ALL BY ADMINISTERING A PRE-BCR COMPLEX ANTAGONIST | February 2022 | December 2024 | Allow | 34 | 4 | 1 | Yes | No |
| 17588205 | PROXIMITY-BASED SORTASE-MEDIATED PROTEIN PURIFICATION AND LIGATION | January 2022 | August 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17630685 | Parvovirus Antibodies for Veterinary Use | January 2022 | June 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17560522 | OPTIMIZED BINUCLEASE FUSIONS AND METHODS | December 2021 | April 2024 | Allow | 28 | 0 | 1 | No | No |
| 17556487 | Polynucleotide-Linked Bioconjugates and Methods of Making and Using | December 2021 | April 2024 | Abandon | 28 | 3 | 1 | No | No |
| 17551582 | EXTRACELLULAR VESICLE COMPRISING A FUSION PROTEIN HAVING FC BINDING CAPACITY | December 2021 | November 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17534029 | BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF | November 2021 | June 2025 | Allow | 43 | 2 | 0 | Yes | Yes |
| 17523058 | Methods of Engineering Surface Charge for Bispecific Antibody Production | November 2021 | July 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17518911 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy | November 2021 | November 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17485561 | Bispecific binding molecules binding to VEGF and Ang2 | September 2021 | June 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17483898 | METHOD FOR PRODUCING POLYPEPTIDE HETERO-OLIGOMER | September 2021 | April 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17468590 | ANTIBODY MIMETIC CAPABLE OF BEING ACTIVATED REVERSIBLY AND USES THEREOF | September 2021 | August 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17466247 | ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF | September 2021 | December 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17464815 | CYS80 CONJUGATED IMMUNOGLOBULINS | September 2021 | March 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17458945 | PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF | August 2021 | February 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17434315 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING THE SAME | August 2021 | May 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17411815 | COMPOSITIONS AND METHODS FOR MAKING ANTIBODY CONJUGATES | August 2021 | February 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17410574 | PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY | August 2021 | July 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17408003 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | August 2021 | September 2024 | Allow | 37 | 2 | 1 | No | No |
| 17407814 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | August 2021 | March 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17393626 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | August 2021 | January 2024 | Allow | 30 | 4 | 1 | Yes | No |
| 17388606 | ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE | July 2021 | September 2024 | Abandon | 37 | 2 | 1 | Yes | No |
| 17424791 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT | July 2021 | February 2024 | Allow | 31 | 4 | 1 | Yes | No |
| 17379822 | MULTI-SPECIFIC BINDING MOLECULES TARGETING ABERRANT CELLS | July 2021 | January 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17374960 | NOVEL ANGIOPOIETIN 2, VEGF DUAL ANTAGONISTS | July 2021 | March 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17343198 | Engineered Immunoglobulin Heavy Chain-Light Chain Pairs and Uses Thereof | June 2021 | April 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17312258 | PROTEASE CLEAVABLE BISPECIFIC ANTIBODIES AND USES THEREOF | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17336152 | BINDING MOLECULES FOR BCMA AND CD3 | June 2021 | December 2024 | Allow | 43 | 7 | 0 | Yes | No |
| 17332598 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | May 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17327837 | MODIFIED ANTIBODIES CONTAINING MODIFIED IGG2 DOMAINS WHICH ELICIT AGONIST OR ANTAGONISTIC PROPERTIES AND USE THEREOF | May 2021 | January 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17324150 | METHODS FOR SITE SPECIFIC CONJUGATION OF PROTEINS CONTAINING GLYCOSYLATED Fc DOMAINS | May 2021 | May 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17320890 | Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways | May 2021 | June 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17307447 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | May 2021 | April 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17290911 | CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS | May 2021 | March 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17306079 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES | May 2021 | February 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17244721 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS | April 2021 | November 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17301704 | FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND CANCER ANTIGENS | April 2021 | July 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17227004 | COMPOSITIONS AND METHODS FOR CONJUGATING ACTIVATABLE ANTIBODIES | April 2021 | January 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17301599 | ANTIBODIES AND CONJUGATES THEREOF | April 2021 | August 2024 | Allow | 41 | 3 | 0 | No | No |
| 17207526 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | March 2021 | May 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17278263 | LIGHT-EMITTING PARTICLE | March 2021 | March 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17203473 | METHODS TO CREATE CHEMICALLY-INDUCED DIMERIZING PROTEIN SYSTEMS FOR REGULATION OF CELLULAR EVENTS | March 2021 | January 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17199332 | FLT3 DIRECTED CAR CELLS FOR IMMUNOTHERAPY | March 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17196498 | PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER | March 2021 | October 2024 | Allow | 43 | 3 | 1 | No | No |
| 17191634 | METHOD FOR IMPROVING THE BENEFIT TO A SUBJECT OF A THERAPY OR THERAPEUTIC AGENT | March 2021 | April 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17187039 | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION | February 2021 | September 2023 | Allow | 30 | 2 | 1 | Yes | Yes |
| 17181913 | ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF | February 2021 | February 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17177543 | NOVEL ANTIBODY FORMAT | February 2021 | November 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17171962 | PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS | February 2021 | February 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17163618 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | February 2021 | October 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17152111 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | January 2021 | December 2024 | Abandon | 47 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUYNH, PHUONG N.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 43.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HUYNH, PHUONG N works in Art Unit 1641 and has examined 418 patent applications in our dataset. With an allowance rate of 85.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner HUYNH, PHUONG N's allowance rate of 85.4% places them in the 57% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HUYNH, PHUONG N receive 2.10 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HUYNH, PHUONG N is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +33.1% benefit to allowance rate for applications examined by HUYNH, PHUONG N. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.8% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 64.2% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 86.4% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 82.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 46.8% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 16.3% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.